In-vitro activity of cefepime and other broad-spectrum antimicrobials against several groups of Gram-negative bacilli and Staphylococcus aureus
- 20 October 1999
- journal article
- Published by Elsevier in Diagnostic Microbiology and Infectious Disease
- Vol. 35 (2) , 121-126
- https://doi.org/10.1016/s0732-8893(99)00062-0
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Antimicrobial Activity and Spectrum Investigation of Eight Broad-Spectrum β-Lactam Drugs: A 1997 Surveillance Trial in 102 Medical Centers in the United StatesDiagnostic Microbiology and Infectious Disease, 1998
- Multicenter evaluation of antimicrobial resistance to six broad-spectrum β-lactams in Colombia using the etest methodDiagnostic Microbiology and Infectious Disease, 1997
- In vitro activity of cefepime and ceftazidime against 197 nosocomial blood stream isolates of streptococci: A multicenter sampleDiagnostic Microbiology and Infectious Disease, 1997
- Risk factors for faecal carriage of Klebsiella pneumoniae producing extended spectrum β-lactamase (ESBL-KP) in the intensive care unitJournal of Hospital Infection, 1997
- Safety of cefepime: A new extended-spectrum parenteral cephalosporinThe American Journal of Medicine, 1996
- Impact of changing pathogens and antimicrobial susceptibility patterns in the treatment of serious infections in hospitalized patientsThe American Journal of Medicine, 1996
- Susceptibility of bacterial isolates to β-lactam antibiotics from U.S. clinical trials over a 5-year periodThe American Journal of Medicine, 1996
- CefepimeDrugs, 1994
- Development of resistance during ceftazidime and cefepime therapy in a murine peritonitis modelJournal of Antimicrobial Chemotherapy, 1992
- Activity of cefepime against ceftazidime- and cefotaxime-resistant gram-negative bacteria and its relationship to beta-lactamase levelsAntimicrobial Agents and Chemotherapy, 1989